RTW INVESTMENTS, LP — 13F Holdings & Portfolio
CIK 1493215 · latest 13F-HR filed 2026-08-14
RTW INVESTMENTS, LP manages $11.71B in 13F-reported U.S. long-equity assets across 84 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are MDGL (9.14%), ARGX (5.62%), PTCT (5.39%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 9 new positions and exited 13; 48 existing positions rose in reported value and 15 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 47.7%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 30, 2026.
7TH FLOOR
NEW YORK, NY 10014
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| AURIGEMA, ROBERT, JOHN Control | PARTNER, CHIEF OPERATING OFFICER AND CHIEF FINANCIAL OFFICER since Aug 2020 | Less than 5% | Individual |
| FONG, PETER, M Control | PARTNER, PRESIDENT since Jan 2022 | Less than 5% | Individual |
| KENNEDY-SMITH, JOSH Control | PARTNER, RESEARCH ANALYST since Jan 2024 | Less than 5% | Individual |
| MAKKER, GOTAM Control | PARTNER, HEAD OF STRATEGIC INVESTMENTS since Sep 2023 | Less than 5% | Individual |
| NGUYEN, TONY Control | PARTNER, RESEARCH ANALYST since Jan 2025 | Less than 5% | Individual |
| PATEL, DARSHAN, VISHNU Control | CHIEF COMPLIANCE OFFICER, GENERAL COUNSEL since Feb 2021 | Less than 5% | Individual |
| RTW INVESTMENTS GP, LLC Control | GENERAL PARTNER OF RTW INVESTMENTS, LP since Apr 2016 | Less than 5% | Domestic Entity |
| SEITER, CHRISTOPHER, JOHN Control | CHIEF CORPORATE FINANCE OFFICER since Apr 2021 | Less than 5% | Individual |
| SIROTA, STEPHANIE, ANNE Control | PARTNER, CHIEF BUSINESS OFFICER since Jan 2014 | Less than 5% | Individual |
| WONG, RODERICK, TZE IAN Control | MANAGING PARTNER, CHIEF INVESTMENT OFFICER since Sep 2009 | 50–75% | Individual |
| YALAMANCHI, NAVEEN Control | PARTNER, PORTFOLIO MANAGER since Jan 2016 | 5–10% | Individual |
Ownership & leadership changes · 13 filings with changes since Oct 31, 2012
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- No longer listedLOUGHRAN, SABERA, REZA · PARTNER EMERITUS · Less than 5% · control person · listed since Oct 2009
- AddedNGUYEN, TONY · PARTNER, RESEARCH ANALYST · Less than 5% · control person
- AddedKENNEDY-SMITH, JOSH · PARTNER, RESEARCH ANALYST · Less than 5% · control person
- ChangedPATEL, DARSHAN, VISHNU · title CHIEF COMPLIANCE OFFICER → CHIEF COMPLIANCE OFFICER, GENERAL COUNSEL
- ChangedWONG, RODERICK, TZE IAN · ownership 75% or more → 50–75%
- ChangedYALAMANCHI, NAVEEN · ownership 10–25% → 5–10%
- AddedMAKKER, GOTAM · PARTNER, HEAD OF STRATEGIC INVESTMENTS · Less than 5% · control person
- ChangedAURIGEMA, ROBERT, JOHN · title CHIEF FINANCIAL OFFICER → PARTNER, CHIEF OPERATING OFFICER AND CHIEF FINANCIAL OFFICER
- ChangedFONG, PETER, M · title PARTNER, CHIEF DEVELOPMENT OFFICER → PARTNER, PRESIDENT
- ChangedLOUGHRAN, SABERA, REZA · title PARTNER, CHIEF ADMINISTRATIVE OFFICER → PARTNER EMERITUS
- ChangedLOUGHRAN, SABERA, REZA · title CHIEF ADMINISTRATIVE OFFICER → PARTNER, CHIEF ADMINISTRATIVE OFFICER
- ChangedSIROTA, STEPHANIE, ANNE · title CHIEF BUSINESS OFFICER → PARTNER, CHIEF BUSINESS OFFICER
- ChangedYALAMANCHI, NAVEEN · ownership 5–10% → 10–25%
- No longer listedLEE, ALICE · SENIOR COUNSEL · Less than 5% · listed since Feb 2019
- AddedFONG, PETER, M · PARTNER, CHIEF DEVELOPMENT OFFICER · Less than 5% · control person
- AddedSEITER, CHRISTOPHER, JOHN · CHIEF CORPORATE FINANCE OFFICER · Less than 5% · control person
- ChangedAURIGEMA, ROBERT, JOHN · now a control person
- ChangedLOUGHRAN, SABERA, REZA · title CHIEF OPERATING OFFICER → CHIEF ADMINISTRATIVE OFFICER
- ChangedPATEL, DARSHAN, VISHNU · now a control person
- ChangedSIROTA, STEPHANIE, ANNE · now a control person
- ChangedWONG, RODERICK, TZE IAN · title MANAGING PARTNER → MANAGING PARTNER, CHIEF INVESTMENT OFFICER
- ChangedYALAMANCHI, NAVEEN · title LIMITED PARTNER → PARTNER, PORTFOLIO MANAGER; now a control person
- AddedSIROTA, STEPHANIE, ANNE · CHIEF BUSINESS OFFICER · Less than 5%
- ChangedLOUGHRAN, SABERA, REZA · ownership 5–10% → Less than 5%
- AddedAURIGEMA, ROBERT, JOHN · CHIEF FINANCIAL OFFICER · Less than 5%
- AddedPATEL, DARSHAN, VISHNU · CHIEF COMPLIANCE OFFICER · Less than 5%
- ChangedLEE, ALICE · title CHIEF COMPLIANCE OFFICER → SENIOR COUNSEL
- ChangedLOUGHRAN, SABERA, REZA · title CHIEF OPERATING OFFICER/CHIEF FINANCIAL OFFICER → CHIEF OPERATING OFFICER
- AddedLEE, ALICE · CHIEF COMPLIANCE OFFICER · Less than 5%
- ChangedLOUGHRAN, SABERA, REZA · title CHIEF OPERATING OFFICER/CHIEF FINANCIAL OFFICER/CHIEF COMPLIANCE OFFICER → CHIEF OPERATING OFFICER/CHIEF FINANCIAL OFFICER
- ChangedLOUGHRAN, SABERA, REZA · ownership Less than 5% → 5–10%
- ChangedYALAMANCHI, NAVEEN · title PORTFOLIO MANAGER → LIMITED PARTNER; no longer a control person
- AddedRTW INVESTMENTS GP, LLC · GENERAL PARTNER OF RTW INVESTMENTS, LP · Less than 5% · control person
- ChangedWONG, RODERICK, TZE IAN · title MANAGING MEMBER → MANAGING PARTNER
Older changes (4 more filings)
- AddedYALAMANCHI, NAVEEN · PORTFOLIO MANAGER · 5–10% · control person
- ChangedLOUGHRAN, SABERA, REZA · title DIRECTOR OF FINANCE & OPERATIONS/CHIEF COMPLIANCE OFFICER → CHIEF OPERATING OFFICER/CHIEF FINANCIAL OFFICER/CHIEF COMPLIANCE OFFICER
- ChangedLOUGHRAN, SABERA, REZA · title DIRECTOR OF FINANCE & OPERATIONS → DIRECTOR OF FINANCE & OPERATIONS/CHIEF COMPLIANCE OFFICER
- ListedLOUGHRAN, SABERA, REZA · DIRECTOR OF FINANCE & OPERATIONS · Less than 5% · control person
- ListedWONG, RODERICK, TZE IAN · MANAGING MEMBER · 75% or more · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- ORUKA THERAPEUTICS INC$197.8M +195.9%
- ULTRAGENYX PHARMACEUTICAL IN$183.9M +240.6%
- SPYRE THERAPEUTICS INC$167.1M +79.4%
- TANGO THERAPEUTICS INC$156.3M +56.2%
- ARGENX SE$140.1M +27.0%
Top Trims
- INSMED INC-$275.6M -34.8%
- COGENT BIOSCIENCES INC-$120.7M -57.5%
- HINGE HEALTH INC-$32.9M -44.2%
- TARSUS PHARMACEUTICALS INC-$23.4M -10.0%
- EVOMMUNE INC-$14.6M -42.2%
New Positions
- KAILERA THERAPEUTICS INC$237.4M
- STRUCTURE THERAPEUTICS INC$86.3M
- AXOGEN INC$46.7M
- DANAHER CORP DEL$43.8M
- SOLID BIOSCIENCES INC$38.9M
Exited Positions
- APOGEE THERAPEUTICS INC$234.2M
- APELLIS PHARMACEUTICALS INC$148.2M
- INTUITIVE SURGICAL INC$101.4M
- CENTESSA PHARMACEUTICALS PLC$81.6M
- CRINETICS PHARMACEUTICALS IN$52.7M
RTW INVESTMENTS, LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | MADRIGAL PHARMACEUTICALS INC | MDGL | 558868105 | $1.07B | 9.14% | 1,993,687 | SH |
| 2 | ARGENX SE | ARGX | 04016X101 | $658.2M | 5.62% | 709,446 | SH |
| 3 | PTC THERAPEUTICS INC | PTCT | 69366J200 | $631.9M | 5.39% | 7,746,415 | SH |
| 4 | PROTAGONIST THERAPEUTICS INC | PTGX | 74366E102 | $620.4M | 5.30% | 5,061,175 | SH |
| 5 | CG ONCOLOGY INC | CGON | 156944100 | $605.0M | 5.16% | 8,514,590 | SH |
| 6 | INSMED INC | INSM | 457669307 | $516.3M | 4.41% | 4,842,880 | SH |
| 7 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $434.5M | 3.71% | 13,900,620 | SH |
| 8 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $377.5M | 3.22% | 4,251,996 | SH |
| 9 | CELCUITY INC | CELC | 15102K100 | $345.8M | 2.95% | 3,304,903 | SH |
| 10 | ERASCA INC | ERAS | 29479A108 | $328.8M | 2.81% | 17,946,754 | SH |
| 11 | RADNET INC | RDNT | 750491102 | $298.9M | 2.55% | 4,846,958 | SH |
| 12 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $298.7M | 2.55% | 3,139,030 | SH |
| 13 | NATERA INC | NTRA | 632307104 | $271.4M | 2.32% | 1,000,000 | SH |
| 14 | ULTRAGENYX PHARMACEUTICAL IN | RARE | 90400D108 | $260.3M | 2.22% | 7,796,895 | SH |
| 15 | IRHYTHM HOLDINGS INC | IRTC | 450056106 | $259.6M | 2.22% | 2,182,631 | SH |
| 16 | CYTOKINETICS INC | CYTK | 23282W605 | $243.8M | 2.08% | 2,862,003 | SH |
| 17 | KAILERA THERAPEUTICS INC | KLRA | 482931102 | $237.4M | 2.03% | 10,776,820 | SH |
| 18 | ESTABLISHMENT LABS HLDGS INC | ESTA | G31249108 | $227.9M | 1.95% | 2,655,695 | SH |
| 19 | GUARDANT HEALTH INC | GH | 40131M109 | $222.2M | 1.90% | 1,481,033 | SH |
| 20 | NEUROCRINE BIOSCIENCES INC | NBIX | 64125C109 | $213.7M | 1.82% | 1,267,925 | SH |
| 21 | TARSUS PHARMACEUTICALS INC | TARS | 87650L103 | $211.3M | 1.80% | 3,357,059 | SH |
| 22 | STOKE THERAPEUTICS INC | STOK | 86150R107 | $184.0M | 1.57% | 5,623,525 | SH |
| 23 | UNIQURE NV | QURE | N90064101 | $181.5M | 1.55% | 3,941,572 | SH |
| 24 | ACADIA PHARMACEUTICALS INC | ACAD | 004225108 | $180.8M | 1.54% | 7,144,524 | SH |
| 25 | REPLIGEN CORP | RGEN | 759916109 | $169.3M | 1.45% | 1,240,637 | SH |
| 26 | UROGEN PHARMA LTD | URGN | M96088105 | $167.2M | 1.43% | 4,543,895 | SH |
| 27 | GH RESEARCH PLC | GHRS | G3855L106 | $159.5M | 1.36% | 5,933,815 | SH |
| 28 | IMMUNOCORE HLDGS PLC | IMCR | 45258D105 | $154.6M | 1.32% | 4,869,798 | SH |
| 29 | COMPASS PATHWAYS PLC | CMPS | 20451W101 | $151.4M | 1.29% | 10,700,974 | SH |
| 30 | IMMATICS N.V | IMTX | N44445109 | $131.1M | 1.12% | 12,946,176 | SH |
| 31 | ZAI LAB LTD | ZLAB | 98887Q104 | $124.9M | 1.07% | 6,574,032 | SH |
| 32 | IMMUNOVANT INC | IMVT | 45258J102 | $122.4M | 1.05% | 3,177,849 | SH |
| 33 | BELITE BIO INC | BLTE | 07782B104 | $110.2M | 0.94% | 715,332 | SH |
| 34 | XENCOR INC | XNCR | 98401F105 | $109.1M | 0.93% | 6,777,461 | SH |
| 35 | TAYSHA GENE THERAPIES INC | TSHA | 877619106 | $92.3M | 0.79% | 13,560,258 | SH |
| 36 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $89.4M | 0.76% | 2,309,021 | SH |
| 37 | ALKERMES PLC | ALKS | G01767105 | $87.6M | 0.75% | 1,672,356 | SH |
| 38 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $86.3M | 0.74% | 1,607,507 | SH |
| 39 | REPLIMUNE GROUP INC | REPL | 76029N106 | $82.0M | 0.70% | 7,411,581 | SH |
| 40 | CASTLE BIOSCIENCES INC | CSTL | 14843C105 | $66.3M | 0.57% | 2,778,335 | SH |
| 41 | CANDEL THERAPEUTICS INC | CADL | 137404109 | $66.1M | 0.56% | 6,422,018 | SH |
| 42 | ROCKET PHARMACEUTICALS INC | RCKT | 77313F106 | $60.5M | 0.52% | 17,687,772 | SH |
| 43 | KODIAK SCIENCES INC | KOD | 50015M109 | $58.0M | 0.49% | 1,487,934 | SH |
| 44 | AKTIS ONCOLOGY INC | AKTS | 01021M104 | $51.3M | 0.44% | 1,592,043 | SH |
| 45 | AXOGEN INC | AXGN | 05463X106 | $46.7M | 0.40% | 1,011,576 | SH |
| 46 | DANAHER CORP DEL | DHR | 235851102 | $43.8M | 0.37% | 230,000 | SH |
| 47 | CULLINAN THERAPEUTICS INC | CGEM | 230031106 | $43.1M | 0.37% | 2,364,347 | SH |
| 48 | NEUROGENE INC | NGNE | 64135M105 | $42.8M | 0.37% | 1,362,456 | SH |
| 49 | HINGE HEALTH INC | HNGE | 433313103 | $41.5M | 0.35% | 500,000 | SH |
| 50 | ORCHESTRA BIOMED HLDGS INC | OBIO | 68572M106 | $41.2M | 0.35% | 9,556,063 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $11.71B | 84 | 0001493215-26-000164 |
| 2026-03-31 | 2026-05-15 | $10.05B | 88 | 0001493215-26-000130 |
| 2025-12-31 | 2026-02-17 | $9.98B | 91 | 0001493215-26-000060 |
| 2025-09-30 | 2025-11-14 | $8.12B | 74 | 0001493215-25-000054 |
7TH FLOOR
NEW YORK, NY 10014